Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps
Diabetes, Obesity and Metabolism · 2024
DOI: 10.1111/dom.15913 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Robert L Dubin und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA. Hauptthemen laut MEDLINE: Weight Loss, Diabetes Mellitus, Type 2, Liraglutide, Exenatide. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 125 Literaturangaben.
Abstract (Originalsprache)
Excess adiposity is at the root of type 2 diabetes (T2D). Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have emerged as first‐line treatments for T2D based on significant weight loss results. The composition of weight loss using most diets consists of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pennington Biomedical Research Center, Baton Rouge, Louisiana, USA.
ORCID-Profile: Robert L Dubin, Steven B Heymsfield, Eric Ravussin, Frank L Greenway
Zitieren
APA
Dubin, R. L., Heymsfield, S. B., Ravussin, E., & Greenway, F. L. (2024). Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15913
Vancouver
Dubin RL, Heymsfield SB, Ravussin E, Greenway FL. Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15913
BibTeX
@article{Dubin2024,
author = {Dubin, Robert L and Heymsfield, Steven B and Ravussin, Eric and Greenway, Frank L},
title = {Glucagon‐like peptide ‐1 receptor agonist ‐based agents and weight loss composition: Filling the gaps},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
doi = {10.1111/dom.15913}
}
EUVIMED